Navigation Links
Preventing variceal bleeding
Date:9/6/2007

Beta blockers should be the first line of prevention against variceal bleeding in patients with cirrhosis and portal hypertension. While banding is similarly effective in reducing the incidence of such bleeding, it can have fatal complications and is more expensive. These findings are published in the September issue of Liver Transplantation, a journal by John Wiley & Sons. The article is also available online via Wiley Interscience at http://www.interscience.wiley.com/journal/livertransplantion

Patients with liver disease often develop portal hypertension from a blockage in the blood flow through the liver. The increased blood pressure in the portal vein causes large veins, called varices, to develop across the esophagus and stomach to bypass the blockage. The se varices become fragile and can bleed easily, causing frightening symptoms like vomiting blood, as well as ascites and encephalopathy. Two ways to prevent variceal bleeding are beta blockers and endoscopic variceal ligation, however it is unclear which is better for patients.

To compare the safety and efficacy of the two therapies in the prevention of primary variceal bleeding, researchers led by Lorenzo Norberto and Lino Polese of the University of Padova in Italy, conducted a randomized controlled trial among patients awaiting liver transplantation. Between September 2001 and December 2005, they enrolled sixty-two patients with Child-B-C cirrhosis and high-risk esophagal varices into their study. The patients were randomly divided between treatment with the beta blocker, propranolol, or variceal banding. All patients had an EGD and a clinical examination every 6 months after beginning treatment.

The 31 patients who took beta blockers started on a low dose and increased it until they achieved a 25 percent reduction of their baseline heart rate. Five patients had to suspend the treatment due to complications including bradycardia, persistent hypotension and vertigo. Of the 26 who continued the treatment, three eventually bled from esophageal varices and two died of such bleeding. During the mean follow-up of 7.6 months, ten of the patients underwent liver transplantation.

Of the 31 patients treated with ligation, two suffered a dramatic hemorrhage a few days after the first treatment and required emergency treatment. One patient recovered, the other died. The remaining patients underwent three ligation sessions to completely eradicate their varices. During the mean follow up of almost 15 months, two patients died of liver failure after 1 and 7 months respectively, while 14 of the patients received a liver transplant.

Both propranolol and endoscopic banding considerably reduced the expected incidence of bleeding, normally 30 percent after one year. The beta blocker lowered the risk to less than 10 percent, the banding to less than 7 percent. Although some patients in each group experienced adverse events related to their treatment, only banding was associated with a death.

Beta blockers should remain the first choice of prophylactic therapy in candidates for liver transplantation, the authors report, though banding should be used when beta-blockers are contraindicated. Both propranolol and endoscopic banding are similarly effective in reducing the incidence of variceal bleeding in cirrhotic patients with high risk varices, but ligation can be complicated by severe and fatal bleeding and is significantly more expensive, they conclude. The mean cost for treatment with propranolol was $1425, compared to $4289 for banding.

In an accompanying editorial, Thomas Boyer of the Liver Research Institute at Arizona Health Sciences Center applauds the strides that have been made however, he says, there are still areas where further studies are warranted in the prevention and management of variceal bleeding. Not all patients treated with beta-blockers benefit from the treatment and remain at high risk for bleeding.

Identification of new drugs that lower portal pressure to the same or greater degree than beta-blockers with fewer side-effects are being sought and if found will further improve the management of the patient with varices, he says.


'/>"/>

Contact: Amy Molnar
amolnar@wiley.com
John Wiley & Sons, Inc.
Source:Eurekalert

Related medicine news :

1. Preventing Childhood Deaths
2. Yoga for preventing weight gain in middle age
3. Preventing mental decline in the aged
4. Preventing white coat hypertension
5. Green tea beneficial in preventing osteoarthritis
6. Preventing Vision Loss
7. Preventing Vision Loss
8. Preventing Colorectal Cancer
9. Preventing Prostate Cancer
10. Lycopene Can Help In Preventing Prostate Cancer
11. Heart Drug Also Effective In Preventing Specific Causes Of Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... The 89th Academy Awards will be celebrated this ... Education Policy Center Bunkum Award. We invite you to enjoy our 11th annual tongue-in-cheek ... winner is the Center for American Progress (CAP), for its report, Lessons From State ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... media outlet with a clinician-based audience, will be participating in Rare Disease Day ... in Washington, D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and ...
(Date:2/23/2017)... CA (PRWEB) , ... February 23, 2017 , ... Los ... two episodes of WE TV’s “Mama June: From Not to Hot,” which will begin ... notable, “Mama” June Shannon, known to millions from the 2012 reality television series, “Here ...
(Date:2/23/2017)... Lawn, NJ (PRWEB) , ... February 23, 2017 ... ... specializing in thought leadership , media relations, content marketing, social media management, ... With several clients already in the state and in nearby New Hampshire, Massachusetts ...
(Date:2/23/2017)... California (PRWEB) , ... February 23, 2017 , ... ... Sports Development will host a diverse symposium on “Doping in Sport: ... Law and Sheppard Mullin Richter & Hampton LLP. The symposium will be held ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 24, 2017 Medivir AB (Nasdaq ... a new Board of Directors that will be submitted ... Committee comprises representatives of the company,s three largest shareholders ... who have accepted a seat on the Nomination Committee, ... the 2016-2017 Nomination Committee was as follows:  ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis ... the global Autism Spectrum Disorder market. The research answers the ... drugs marketed for Autism Spectrum Disorder and their clinical attributes? How ...
(Date:2/23/2017)... 2017 ITL Limited, ( ASX: ITD ), an innovative ... half year ended 31 December 2016 compared with the previous corresponding ... be viewed here . Highlights ... 104%) Earnings per share of 2.2 cents (Dec ... (Dec 2015: $15.7m; up 11%) Profit before tax ...
Breaking Medicine Technology: